Telo Genomics Corp. is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging (ASI) California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.
The assessment focuses on processing and comparing analysis results of identical samples achieved using ASI GenASIs™ HiFISH automation solution and the traditional TELO’s workflow
The potential integration of ASI GenASIs™ automation and image analysis solutions into TELO’s workflow targets to augment the efficiency and consistency of TELO’s workflow, and at the same time decrease the laboratory’s processing time (Turnaround Time) and cost. The added value has the potential to expedite the adoption of TELO’s technology in the clinic. Future directions for the collaboration between ASI and Telo will be defined based on the compatibility and concordance of the two workflows.
“I look forward to the promising results from this assessment in partnership with ASI. ASI offers world class automation solutions, and has been a long-term collaborator”, said Sabine Mai, TELO’s co-Founder, Director and Chair of the Clinical and Scientific Advisory Board.
“We are excited to launch this assessment with Telo Genomics, we trust ASI technology will offer added value to TELO’s workflow. ASI GenASIs™ solutions gained several FDA clearances for diagnostic and prognostic tests already in the clinic”, said Limor Shiposh, ASI CEO.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.
About Applied Spectral Imaging
ASI is a global leader and provider of biomedical imaging and analysis solutions with a comprehensive product portfolio in digital diagnostics. Founded in 1993, ASI markets, services, and supports its products in more than 50 countries. The company has worldwide offices in the US and Asia, plus a global network of distribution partners.
For more information about ASI’s products and clinical applications, please visit the company’s website at https://spectral-imaging.com/
For further information, please contact:
Hugh Rogers
Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
